Back to top
more

C4 Therapeutics (CCCC)

(Real Time Quote from BATS)

$6.50 USD

6.50
1,041,031

+0.06 (0.93%)

Updated Jul 26, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CCCC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

C4 Therapeutics, Inc. [CCCC]

Reports for Purchase

Showing records 1 - 20 ( 20 total )

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/26/2024

Company Report

Pages: 3

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

12/13/2023

Daily Note

Pages: 4

CFT7455 Data Support Accelerated Approval Pathway in BCMA Refractory Patients, Indicate Opportunities in Early Lines

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/02/2023

Company Report

Pages: 8

All Eyes on CFT7455 As C4 Culls BRD9 Program; Reiterate Buy; PT Down to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/09/2023

Company Report

Pages: 8

Multiple Data Readouts in 2H 2023 Might Test the Strength of Torpedo; Reiterate Buy and Lowering PT to $17 from $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/08/2023

Company Report

Pages: 8

Thoughts on CFT8634 C4?s BRD9 Degrader; Reit. Buy; PT Down to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/24/2023

Company Report

Pages: 7

Insights on the Phase 1/2 CFT8634 Data in 2H 2023; Reit. Buy and $35 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/14/2022

Industry Report

Pages: 4

Cereblon Dumps Thalidomide for Better Degrons?Takeaways From The 5th Targeted Protein Degradation Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/04/2022

Company Report

Pages: 7

CFT1946, A New Foe for the Undruggable BRAF Mutant Solid Tumors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/11/2022

Industry Report

Pages: 9

Treatment Paradigm Pulse-A Prospective Look at EGFR Inhibitors in NSCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/05/2022

Company Report

Pages: 7

Thoughts on Phase 1/2 Study of CFT8634-Teachings from PALETTE

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/02/2022

Industry Report

Pages: 5

Learnings From FASEB?s Ubiquitin Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/09/2022

Company Report

Pages: 7

Thoughts on CFT1946 in BRAF V600X-Driven Cancers as C4 Plans for a Phase 1 in 2H 2022; Reit. Buy; Lower PT to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

04/11/2022

Daily Note

Pages: 4

AACR Data Indicates CFT7455?s Deep Degradation Potential with On-Target Safety Issues Guiding Future Trial Design

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

02/25/2022

Company Report

Pages: 7

Considerations For CFT7455 Data Readout at AACR in April 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/11/2021

Company Report

Pages: 7

CFT7455 Dose Escalation Data On Track for 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CCCC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/12/2021

Company Report

Pages: 7

CFT7455 and CFT8919 Setting the Stage for Protein Degradation Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

06/22/2021

Daily Note

Pages: 4

CFT7455?s New Data Supports Further Clinical Development in NH L? Our Thoughts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

06/08/2021

Company Report

Pages: 4

CFT8919 Preclinical Data Bodes Well for the Platform - Our Insights

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: C4 Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/04/2021

Company Report

Pages: 76

Hone, Seek, Target and Destroy Disease-Causing Proteins Using TORPEDO; Initiate With Buy and $63 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 150.00

Research Provided by a Third Party